SRCM
JSPR icon

Sage Rock Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Sage Rock Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-46,356
Closed -$4.59M – 222
2021
Q1 		$4.59M Hold
46,356
– – 0.55% 100
2020
Q4 		$4.64M Hold
46,356
– – 0.77% 63
2020
Q3 		$4.6M Buy
46,356
+5,716
+14% +$571K 0.91% 45
2020
Q2 		$4.17M Hold
40,640
– – 1.25% 30
2020
Q1 		$3.86M Buy
+40,640
New +$3.98M 1.59% 25

Other funds holding JSPR

MSU
Mizuho Securities USA New York $4.24B AUM 22.54% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
DCM
Dupont Capital Management Wilmington, Delaware $879M AUM 29.99% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return

Sage Rock Capital Management's JSPR Position: Q2 2021 in Review

Sage Rock Capital Management sold out of Jasper Therapeutics (JSPR) in Q2 2021, closing a stake of 46,356 shares — an estimated $4.59M sold.

Sage Rock Capital Management first reported a position in JSPR in Q1 2020 and held it in 5 quarters. The position peaked at $4.64M in Q4 2020. 57 funds tracked by Wall St. Rank hold JSPR as of Q2 2021.

  • Sage Rock Capital Management reported no remaining Jasper Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Sage Rock Capital Management sold 46,356 Jasper Therapeutics shares in Q2 2021, an estimated $4.59M.
  • Sage Rock Capital Management first reported a position in Jasper Therapeutics in Q1 2020 and held it in 5 quarters.
  • Sage Rock Capital Management's Jasper Therapeutics position peaked at $4.64M in Q4 2020.
  • 57 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2021.

Based on Sage Rock Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.